We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

12 hedge funds and large institutions have $5.79M invested in Traws Pharma in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 12 → 12 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

30% less capital invested

Capital invested by funds: $8.23M → $5.79M (-$2.44M)

86% less call options, than puts

Call options by funds: $1K | Put options by funds: $7K

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
5
Calls
$1K
Puts
$7K
Net Calls
-$6K
Net Calls Change
+$33K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$978K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$734K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$245K
4
Deutsche Bank
Deutsche Bank
Germany
+$245K
5
Millennium Management
Millennium Management
New York
+$245K

Top Sellers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
-$1.5M
2
BFA
BlackRock Fund Advisors
California
-$1.22M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$615K
4
ARTA
A.R.T. Advisors
New York
-$245K
5
HighTower Advisors
HighTower Advisors
Illinois
-$245K
Name Holding Trade Value Shares
Change 		Change in
Stake
GPP
1
Great Point Partners
Connecticut
$1.82M +$978K +4 +67%
Vanguard Group
2
Vanguard Group
Pennsylvania
$870K +$245K +1 +25%
WMSA
3
Weiss Multi-Strategy Advisers
New York
$584K +$245K +1 +50%
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$487K +$734K +3 New
Citigroup
5
Citigroup
New York
$348K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$213K – – –
AFM
7
Anson Funds Management
Texas
$165K +$245K +1 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$150K – – –
Deutsche Bank
9
Deutsche Bank
Germany
$135K +$245K +1 New
Millennium Management
10
Millennium Management
New York
$117K +$245K +1 New
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$108K – – –
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$107K +$245K +1 New
BFA
13
BlackRock Fund Advisors
California
$84K -$1.22M -5 Closed
SIM
14
Spark Investment Management
New York
$84K – – –
Goldman Sachs
15
Goldman Sachs
New York
$83K – – –
PP
16
Paloma Partners
Connecticut
$64K – – –
HighTower Advisors
17
HighTower Advisors
Illinois
$60K -$245K -1 Closed
ARTA
18
A.R.T. Advisors
New York
$59K -$245K -1 Closed
HK
19
Horizon Kinetics
New York
$59K – – –
Northern Trust
20
Northern Trust
Illinois
$42K – – –
BCM
21
Bridgeway Capital Management
Texas
$39K – – –
Janney Montgomery Scott
22
Janney Montgomery Scott
Pennsylvania
$37.9K – – –
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$22K – – –
Bank of America
24
Bank of America
North Carolina
$13K – – –
UBS Group
25
UBS Group
Switzerland
$13K – – –
1
2

TRAW Hedge Fund Activity: Q4 2014 in Review

12 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2014, worth a combined $5.79M — down 30% from $8.23M a quarter earlier.

Fund positioning in TRAW was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Great Point Partners, adding an estimated $978K. The largest seller was Sarissa Capital Management, exiting entirely with an estimated $1.5M sold.

  • 12 institutional investors held Traws Pharma (TRAW) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $5.79M of Traws Pharma stock for Q4 2014, down 30% quarter-over-quarter.
  • 5 funds opened new Traws Pharma positions in Q4 2014 and 5 closed out, a net change of 0 holders.
  • The largest Traws Pharma buyer in Q4 2014 was Great Point Partners, an estimated $978K added.
  • The largest Traws Pharma seller in Q4 2014 was Sarissa Capital Management, an estimated $1.5M sold.

Based on aggregated 13F filings for Q4 2014.